Header Logo

Connection

SETH LERNER to Aged

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Aged.
SETH LERNER
Connection Strength
1.584
Aged
  1. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
    View in: PubMed
    Score: 0.068
  2. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr; 207(4):779-788.
    View in: PubMed
    Score: 0.056
  3. Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. Urol Oncol. 2021 07; 39(7):434.e23-434.e29.
    View in: PubMed
    Score: 0.053
  4. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma. Cancer Chemother Pharmacol. 2021 06; 87(6):799-805.
    View in: PubMed
    Score: 0.053
  5. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
    View in: PubMed
    Score: 0.050
  6. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8.
    View in: PubMed
    Score: 0.035
  7. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012 Sep; 110(5):630-6.
    View in: PubMed
    Score: 0.028
  8. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun; 30(3):285-9.
    View in: PubMed
    Score: 0.026
  9. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008 Jul; 72(1):133-7.
    View in: PubMed
    Score: 0.022
  10. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):155-9.
    View in: PubMed
    Score: 0.021
  11. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422.
    View in: PubMed
    Score: 0.020
  12. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006 Nov 15; 12(22):6663-76.
    View in: PubMed
    Score: 0.020
  13. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2.
    View in: PubMed
    Score: 0.019
  14. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006 Dec; 50(6):1254-60; discussion 1261-2.
    View in: PubMed
    Score: 0.019
  15. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 2005 Aug; 66(2):441-6.
    View in: PubMed
    Score: 0.018
  16. Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. J Clin Oncol. 2005 Jul 01; 23(19):4458-9.
    View in: PubMed
    Score: 0.018
  17. Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. J Clin Oncol. 2005 Jul 01; 23(19):4459-60.
    View in: PubMed
    Score: 0.018
  18. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Jul; 48(1):69-76.
    View in: PubMed
    Score: 0.017
  19. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
    View in: PubMed
    Score: 0.017
  20. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 Oct 01; 7(10):e2437871.
    View in: PubMed
    Score: 0.017
  21. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
    View in: PubMed
    Score: 0.017
  22. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025 Feb; 135(2):260-268.
    View in: PubMed
    Score: 0.017
  23. Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 08 01; 7(8):e2425288.
    View in: PubMed
    Score: 0.017
  24. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 10; 134(4):596-601.
    View in: PubMed
    Score: 0.017
  25. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
    View in: PubMed
    Score: 0.017
  26. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 07 01; 7(7):e2419966.
    View in: PubMed
    Score: 0.017
  27. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
    View in: PubMed
    Score: 0.017
  28. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.016
  29. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004 May; 171(5):1830-4.
    View in: PubMed
    Score: 0.016
  30. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
    View in: PubMed
    Score: 0.016
  31. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
    View in: PubMed
    Score: 0.016
  32. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):626-30.
    View in: PubMed
    Score: 0.016
  33. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003 Dec; 170(6 Pt 1):2244-7.
    View in: PubMed
    Score: 0.016
  34. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
    View in: PubMed
    Score: 0.016
  35. Bacillus Calmette-Gu?rin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials. 2023 Oct 04; 24(1):636.
    View in: PubMed
    Score: 0.016
  36. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
    View in: PubMed
    Score: 0.015
  37. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.015
  38. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer. 2002 Dec 15; 95(12):2494-9.
    View in: PubMed
    Score: 0.015
  39. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002 Mar; 167(3):1475-81.
    View in: PubMed
    Score: 0.014
  40. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):16-22.
    View in: PubMed
    Score: 0.014
  41. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.013
  42. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
    View in: PubMed
    Score: 0.013
  43. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.013
  44. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
    View in: PubMed
    Score: 0.013
  45. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.013
  46. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.013
  47. Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential. Urol Oncol. 2020 03; 38(3):78.e15-78.e21.
    View in: PubMed
    Score: 0.012
  48. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.012
  49. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 04; 77(4):420-433.
    View in: PubMed
    Score: 0.012
  50. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.012
  51. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
    View in: PubMed
    Score: 0.012
  52. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 08; 76(2):200-206.
    View in: PubMed
    Score: 0.012
  53. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Feb; 161(2):500-4.
    View in: PubMed
    Score: 0.011
  54. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888.
    View in: PubMed
    Score: 0.011
  55. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216.
    View in: PubMed
    Score: 0.011
  56. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804.
    View in: PubMed
    Score: 0.011
  57. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
    View in: PubMed
    Score: 0.010
  58. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 1997 Oct; 15(10):3214-22.
    View in: PubMed
    Score: 0.010
  59. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
    View in: PubMed
    Score: 0.010
  60. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.010
  61. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554.
    View in: PubMed
    Score: 0.010
  62. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.010
  63. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 01; 123(5):794-801.
    View in: PubMed
    Score: 0.010
  64. Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
    View in: PubMed
    Score: 0.009
  65. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016 06; 27(6):1100-1106.
    View in: PubMed
    Score: 0.009
  66. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
    View in: PubMed
    Score: 0.009
  67. External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. J Urol. 2016 Feb; 195(2):283-9.
    View in: PubMed
    Score: 0.009
  68. Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ. 2014 Dec; 29(4):739-45.
    View in: PubMed
    Score: 0.009
  69. Renal cell carcinoma extending into the retrohepatic inferior vena cava. Tex Heart Inst J. 2014 Dec; 41(6):671-2.
    View in: PubMed
    Score: 0.009
  70. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15; 120(8):1272-80.
    View in: PubMed
    Score: 0.008
  71. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu?rin. J Urol. 2013 Oct; 190(4):1200-4.
    View in: PubMed
    Score: 0.008
  72. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993 Apr; 149(4):758-64; discussion 764-5.
    View in: PubMed
    Score: 0.008
  73. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
    View in: PubMed
    Score: 0.007
  74. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013 Jun; 111(8):1215-21.
    View in: PubMed
    Score: 0.007
  75. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
    View in: PubMed
    Score: 0.007
  76. Racial/ethnic differences in upper-tract urothelial cancer. Ethn Dis. 2012; 22(3):295-301.
    View in: PubMed
    Score: 0.007
  77. The risk of dying of prostate cancer in patients with clinically localized disease. J Urol. 1991 Oct; 146(4):1040-5.
    View in: PubMed
    Score: 0.007
  78. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
    View in: PubMed
    Score: 0.007
  79. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.007
  80. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
    View in: PubMed
    Score: 0.007
  81. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.007
  82. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94.
    View in: PubMed
    Score: 0.006
  83. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.006
  84. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70.
    View in: PubMed
    Score: 0.006
  85. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May; 183(5):1757-63.
    View in: PubMed
    Score: 0.006
  86. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
    View in: PubMed
    Score: 0.006
  87. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
    View in: PubMed
    Score: 0.006
  88. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
    View in: PubMed
    Score: 0.006
  89. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.006
  90. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
    View in: PubMed
    Score: 0.006
  91. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13.
    View in: PubMed
    Score: 0.006
  92. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug; 182(2):459-65; discussion 465.
    View in: PubMed
    Score: 0.006
  93. Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience. Transplant Proc. 2009 Jun; 41(5):1713-6.
    View in: PubMed
    Score: 0.006
  94. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May; 103(10):1359-62.
    View in: PubMed
    Score: 0.006
  95. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
    View in: PubMed
    Score: 0.005
  96. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008 Jul; 180(1):116-20.
    View in: PubMed
    Score: 0.005
  97. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008 Feb; 71(2):302-7.
    View in: PubMed
    Score: 0.005
  98. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
    View in: PubMed
    Score: 0.005
  99. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.005
  100. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008 Feb; 101(4):450-4.
    View in: PubMed
    Score: 0.005
  101. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int. 2007 Nov; 100(5):1015-20.
    View in: PubMed
    Score: 0.005
  102. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.005
  103. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007 Mar; 51(3):699-706; discussion 706-8.
    View in: PubMed
    Score: 0.005
  104. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3):538-42.
    View in: PubMed
    Score: 0.005
  105. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007 Jan; 51(1):152-60.
    View in: PubMed
    Score: 0.005
  106. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.005
  107. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007 Jan; 51(1):137-49; discussion 149-51.
    View in: PubMed
    Score: 0.005
  108. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun; 175(6):2048-53; discussion 2053.
    View in: PubMed
    Score: 0.005
  109. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.005
  110. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol. 2006 May; 175(5):1645-9; discussion 1649.
    View in: PubMed
    Score: 0.005
  111. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84.
    View in: PubMed
    Score: 0.005
  112. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
    View in: PubMed
    Score: 0.005
  113. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93.
    View in: PubMed
    Score: 0.005
  114. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 Sep 20; 23(27):6533-9.
    View in: PubMed
    Score: 0.005
  115. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
    View in: PubMed
    Score: 0.005
  116. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005 Apr; 29(4):443-51.
    View in: PubMed
    Score: 0.004
  117. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004 May; 171(5):1823-8; discussion 1827-8.
    View in: PubMed
    Score: 0.004
  118. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.004
  119. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.004
  120. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62.
    View in: PubMed
    Score: 0.004
  121. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia. 2002 Apr; 16(4):632-5.
    View in: PubMed
    Score: 0.004
  122. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.003
  123. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6.
    View in: PubMed
    Score: 0.003
  124. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5.
    View in: PubMed
    Score: 0.003
  125. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18; 93(8):597-604.
    View in: PubMed
    Score: 0.003
  126. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70.
    View in: PubMed
    Score: 0.003
  127. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
    View in: PubMed
    Score: 0.003
  128. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 01; 97(1):256-63.
    View in: PubMed
    Score: 0.003
  129. Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg. 2000 Sep; 232(3):312-23.
    View in: PubMed
    Score: 0.003
  130. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun; 24(6):469-74.
    View in: PubMed
    Score: 0.003
  131. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):71-85.
    View in: PubMed
    Score: 0.003
  132. The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. Yonsei Med J. 1999 Apr; 40(2):118-23.
    View in: PubMed
    Score: 0.003
  133. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
    View in: PubMed
    Score: 0.003
  134. Chronic lymphocytic leukemia in the young patient. Semin Oncol. 1998 Feb; 25(1):107-16.
    View in: PubMed
    Score: 0.003
  135. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997 Oct; 11(10):1631-5.
    View in: PubMed
    Score: 0.003
  136. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul; 48(1):28-32.
    View in: PubMed
    Score: 0.002
  137. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9.
    View in: PubMed
    Score: 0.002
  138. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995 Aug 15; 86(4):1298-300.
    View in: PubMed
    Score: 0.002
  139. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun; 10(3):187-93.
    View in: PubMed
    Score: 0.002
  140. L-asparaginase and PEG asparaginase--past, present, and future. Leuk Lymphoma. 1993; 10 Suppl:153-7.
    View in: PubMed
    Score: 0.002
  141. The role of transrectal ultrasonography in the diagnosis and management of prostatic and seminal vesicle cysts. J Urol. 1989 May; 141(5):1206-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.